Skip to main content
RecallFDAfda-F-1237-2024OTHER

Organic Yogi Echinacea Immune Support, Caffeine Herbal Supplement, Serving Size 1 tea bag, 16 tea bags per pack, 4 packs per box. UPC on ...

Category
Units Affected
54,846
Recall Date
March 12, 2024
Issuing Agency
Hazard
Other

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1237-2024.

Organic Yogi Echinacea Immune Support product is recalled because pesticide residues were detected above action levels.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1237-2024.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact East West Tea Company, Llc or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1237-2024.

East West Tea Company, LLC

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

East West Tea Company, Llc Recall FAQ

East West Tea Company, Llc is the subject of a beverages safety report: Organic Yogi Echinacea Immune Support, Caffeine Herbal Supplement, Serving Size 1 tea bag, 16 tea bags per pack, 4 packs per box. UPC on .... The notice was published on March 12, 2024 by the U.S. Food and Drug Administration (FDA). Approximately 54,846 units are potentially affected.